Prudence Ive
Overview
Explore the profile of Prudence Ive including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inzaule S, Kroeze S, Kityo C, Siwale M, Akanmu S, Wellington M, et al.
AIDS
. 2022 May;
36(10):1437-1447.
PMID: 35608116
Objective: In a multicountry prospective cohort of persons with HIV from six countries between 2007 and 2015, we evaluated long-term outcomes of first-line non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy (ART), and...
2.
Picton A, Paximadis M, Koor G, Bharuthram A, Shalekoff S, Lassauniere R, et al.
Front Immunol
. 2022 Jan;
12:781263.
PMID: 34987508
Unique Individuals who exhibit either suppressive HIV-1 control, or the ability to maintain low viral load set-points and preserve their CD4+ T cell counts for extended time periods in the...
3.
Richards L, Spencer D, Nel J, Ive P
S Afr J Infect Dis
. 2021 Sep;
35(1):169.
PMID: 34485477
Background: Infectious diseases (IDs) dominate the disease profile in South Africa (SA) and the ID department is increasingly valuable. There has been little evaluation of the IDs consultation services in...
4.
Kendall M, Lalloo U, Fletcher C, Wu X, Podany A, Cardoso S, et al.
Clin Infect Dis
. 2021 Aug;
73(4):706-715.
PMID: 34398956
Background: Protease inhibitor-based antiretroviral therapy may be used in resource-limited settings in persons with human immunodeficiency virus and tuberculosis (HIV-TB). Data on safety, pharmacokinetics/pharmacodynamics (PK/PD), and HIV-TB outcomes for lopinavir/ritonavir...
5.
Nel J, Ive P, Nel C
South Afr J HIV Med
. 2021 Aug;
22(1):1257.
PMID: 34394972
No abstract available.
6.
Inzaule S, Bertagnolio S, Kityo C, Siwale M, Akanmu S, Wellington M, et al.
AIDS
. 2020 Jul;
34(10):1559-1566.
PMID: 32675566
Introduction: To achieve viral suppression among more than 90% of people on antiretroviral therapy (ART), improved understanding is warranted of the modifiable causes of HIV viremic episodes. We assessed the...
7.
Govender N, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, et al.
South Afr J HIV Med
. 2020 Mar;
20(1):1030.
PMID: 32201629
No abstract available.
8.
Inzaule S, Kityo C, Siwale M, Akanmu A, Wellington M, de Jager M, et al.
Sci Rep
. 2018 Oct;
8(1):15751.
PMID: 30361640
In ART programs in sub-Saharan Africa, a growing proportion of HIV-infected persons initiating first-line antiretroviral therapy (ART) have a history of prior antiretroviral drug use (PAU). We assessed the effect...
9.
Steinhaus N, Al-Talib M, Ive P, Boyles T, Bamford C, Davies M, et al.
Int J Infect Dis
. 2018 Jun;
73:78-84.
PMID: 29908251
Objectives: Data on the management and outcomes of Staphylococcus aureus bacteraemia (SAB) in resource-limited settings are limited. The aim of this study was to describe a cohort of South African...
10.
Evans D, Hirasen K, Berhanu R, Malete G, Ive P, Spencer D, et al.
AIDS Res Ther
. 2018 Apr;
15(1):10.
PMID: 29636106
Background: While efficacy data exist, there are limited data on the outcomes of patients on third-line antiretroviral therapy (ART) in sub-Saharan Africa in actual practice. Being able to identify predictors...